• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    How Icotyde Phase 3 Success At J&J Has Changed Its Investment Story

    Simply Wall St·11/09/2026 13:25:59
    Listen to the news
    • Johnson & Johnson reported a series of recent R&D wins, including Phase 3 success for oral ICOTYDE in psoriatic arthritis, accelerated FDA approval of RYBREVANT FASPRO in head and neck cancer, and encouraging early data for pasritamig plus JNJ-9401 in advanced prostate cancer.
    • These updates point to Johnson & Johnson’s drug pipeline moving from slide decks into real-world use, with late-stage readouts, new approvals and first-in-human prostate cancer data all feeding into the same commercial story.
    • Next, the focus shifts to how Johnson & Johnson’s investment narrative absorbs ICOTYDE’s Phase 3 readout and the broader pipeline momentum.

    Scan Johnson & Johnson’s R&D momentum against a curated set of healthcare peers by focusing on stocks screened as list of solid balance sheet and fundamentals (25 results)

    Johnson & Johnson Investment Narrative Recap

    To remain a shareholder in Johnson & Johnson, you need to believe management can turn a strong product pipeline and almost US$100b in yearly sales into steadier earnings after a year with one off hits and lower margins at 16.2% versus 27.2%. The recent oncology and immunology updates support the idea that the Innovative Medicine engine still has room to work for the business.

    The near term hinge point is whether execution improves in areas where leadership has admitted MedTech performance is below its own standard, while pressures such as Abiomed softness and Middle East disruption still sit in the background. The new data and approvals may help sentiment, but they do not fully resolve those operational questions yet.

    LunaRodas, a Simply Wall St Community investor who wrote the narrative, argues that Johnson & Johnson’s long term story rests on portfolio depth in areas such as oncology and immunology. The first in human results for pasritamig plus JNJ 9401 in advanced prostate cancer support that view, because they show early PSA responses in a hard to treat setting with 73% of patients reaching at least a 50% decline.

    Those prostate cancer data, together with ICOTYDE’s Phase 3 results in psoriatic arthritis and RYBREVANT FASPRO’s accelerated approval in head and neck cancer, give Johnson & Johnson several potential contributors to future Innovative Medicine revenue. For investors tracking catalysts, the focus is on how efficiently the firm moves these assets through later stage trials, manages safety as exposure widens, and integrates any future launches while working to rebuild profit margins.

    LunaRodas anchors the narrative’s fair value for Johnson & Johnson at US$240.69, based on the view that double digit growth by the end of the decade links portfolio depth, pipeline catalysts, and current execution into a coherent long term earnings path.

    Uncover why Johnson & Johnson's fair value indicates a 13% potential downside to its current price, leaving little room for error.

    NYSE:JNJ 1-Year Stock Price Chart
    NYSE:JNJ 1-Year Stock Price Chart

    Exploring Other Perspectives

    Some analysts were far more cautious on Johnson & Johnson before this news, arguing that heavy reliance on high expectation oncology drugs was the real swing factor. The most pessimistic group still penciled in revenue of about US$120.1b and earnings of US$28.9b by 2029, yet viewed that as only just enough, which shows how sharply opinions can differ and why it is worth exploring several viewpoints that may now evolve after these trial updates.

    Explore 9 other Johnson & Johnson fair value estimates, including one that suggests as much as 16% downside from the current price.

    The Verdict Is Yours

    Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

    Looking For More Investment Ideas Beyond Johnson & Johnson?

    If the Johnson & Johnson story has you thinking about where else strong balance sheets, income potential, or mispriced businesses might exist, the Simply Wall St Screener can help you widen the net without losing focus.